Bal Pharma Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Bal Pharma Ltd reported a 0.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 9.9%.
- Its expenses for the quarter were up by 1.3% QoQ and down 9.2% YoY.
- The net profit decreased 50.0% QoQ and decreased 38.8% YoY.
- The earnings per share (EPS) of Bal Pharma Ltd stood at 0.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 73.66 | 73.49 | 81.76 | 0.2% | -9.9% |
Total Expenses | 73.10 | 72.13 | 80.49 | 1.3% | -9.2% |
Profit Before Tax | 0.57 | 1.36 | 1.27 | -58.1% | -55.1% |
Tax | 0.05 | 0.32 | 0.42 | -84.4% | -88.1% |
Profit After Tax | 0.52 | 1.04 | 0.85 | -50.0% | -38.8% |
Earnings Per Share | 0.30 | 0.70 | 0.50 | -57.1% | -40.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bal Pharma Ltd operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical formulations. The company provides a range of products including generics, branded formulations, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). Bal Pharma serves both domestic and international markets, leveraging its manufacturing capabilities to meet diverse healthcare needs. As of the most recent updates, there are no specific major developments available for Bal Pharma Ltd.
Revenue
During the third quarter of fiscal year 2025 (Q3FY25), Bal Pharma Ltd reported a total income of ₹73.66 crores. This represents a slight quarter-over-quarter (QoQ) increase of 0.2% from ₹73.49 crores in the second quarter of fiscal year 2025 (Q2FY25). However, there was a year-over-year (YoY) decline of 9.9% compared to ₹81.76 crores in the third quarter of fiscal year 2024 (Q3FY24). The revenue figures reflect the company's ability to sustain its income in the current quarter while highlighting a decrease compared to the same quarter in the previous year.
Profitability
In Q3FY25, Bal Pharma Ltd's profit before tax was ₹0.57 crores, which marked a significant QoQ decrease of 58.1% from ₹1.36 crores in Q2FY25 and a YoY decline of 55.1% from ₹1.27 crores in Q3FY24. The tax expense for Q3FY25 stood at ₹0.05 crores, down 84.4% QoQ from ₹0.32 crores and 88.1% YoY from ₹0.42 crores. Consequently, the profit after tax for Q3FY25 was ₹0.52 crores, a reduction of 50.0% QoQ from ₹1.04 crores and 38.8% YoY from ₹0.85 crores. The earnings per share in Q3FY25 was ₹0.30, which decreased by 57.1% QoQ from ₹0.70 and 40.0% YoY from ₹0.50, indicating the company's current profitability status.
Operating Metrics
Bal Pharma Ltd's total expenses in Q3FY25 amounted to ₹73.10 crores, showing a 1.3% increase QoQ from ₹72.13 crores in Q2FY25. There was a YoY decrease of 9.2% from ₹80.49 crores in Q3FY24. The data highlights the company's ongoing expense management amid revenue fluctuations. The consistent expense levels relative to income suggest operational stability despite the reduced profitability metrics. The analysis of these operating metrics provides an insight into the company's financial health and operational efficiency in the given quarter.
